Non-Hispanic (NH) white | 199 913 (62.0) | ||
Hispanic (all races) | 59 204 (18.4) | ||
NH Asian or Pacific Islander | 41 811 (13.0) | ||
NH black | 20 073 (6.2) | ||
NH American Indian/Alaska Native | 1347 (0.4) | ||
Total | 322 348 | ||
All races/ethnicity (N=3 22 348) | Hispanic (N=59 204) | Black (N=20 073) | |
Vital status (n, %) | |||
Alive | 273 455 (84.8) | 50 382 (85.1) | 15 175 (75.6) |
Dead | 48 893 (15.2) | 8822 (14.9) | 4898 (24.4) |
Survival months | |||
Min, Max | 0.0, 227.0 | 0.0, 227.0 | 0.0, 227.0 |
Mean | 90.4 | 80.6 | 82.9 |
Median | 79.0 | 67.0 | 69.0 |
SD | 60.9 | 58.7 | 59.8 |
Age | |||
Min, Max | 19.0, 100.0 | 19.0, 99.0 | 19.0, 100.0 |
Mean | 59.1 | 55.3 | 57.8 |
Median | 59.0 | 54.0 | 57.0 |
SD | 13.0 | 12.9 | 13.0 |
First malignant primary indicator (n, %) | |||
Y | 278 117 (86.3) | 53 174 (89.8) | 17 240 (85.9) |
N | 44 231 (13.7) | 6030 (10.2) | 2833 (14.1) |
Sequence no of tumours (n, %) | |||
One primary only | 236 182 (73.3) | 46 956 (79.3) | 14 650 (73.0) |
Second of two or more primaries | 44 226 (13.7) | 6233 (10.5) | 2812 (14.0) |
First of two or more primaries | 34 893 (10.8) | 5328 (9.0) | 2152 (10.7) |
Third of three or more primaries | 6008 (1.9) | 603 (1.0) | 397 (2.0) |
Fourth of four or more primaries | 878 (0.3) | 75 (0.1) | 51 (0.3) |
Other | 161 (0.0) | 9 (0.0) | 11 (0.1) |
Histology (n, %) | |||
Ductal and lobular neoplasms | 306 634 (95.1) | 56 417 (95.3) | 18 904 (94.2) |
Cystic, mucinous and serous neoplasms | 5800 (1.8) | 1001 (1.7) | 411 (2.0) |
Adenomas and adenocarcinomas | 5063 (1.6) | 768 (1.3) | 294 (1.5) |
Epithelial neoplasms, NOS | 1343 (0.4) | 279 (0.5) | 139 (0.7) |
Complex epithelial neoplasms | 1311 (0.4) | 258 (0.4) | 154 (0.8) |
Adnexal and skin appendage neoplasms | 807 (0.3) | 136 (0.2) | 65 (0.3) |
Squamous cell neoplasms | 573 (0.2) | 116 (0.2) | 52 (0.3) |
Fibroepithelial neoplasms | 385 (0.1) | 141 (0.2) | 19 (0.1) |
Other | 432 (0.1) | 88 (0.1) | 35 (0.2) |
Total no of in situ/malignant tumours (n, %) | |||
1 | 239 762 (74.4) | 47 536 (80.3) | 14 880 (74.1) |
2 | 67 146 (20.8) | 10 046 (17.0) | 4224 (21.0) |
3 | 12 622 (3.9) | 1387 (2.3) | 802 (4.0) |
4 | 2276 (0.7) | 206 (0.3) | 141 (0.7) |
5+ | 542 (0.2) | 29 (0.0) | 26 (0.1) |
Summary stage (n, %) | |||
Localised | 205 612 (63.8) | 34 061 (57.5) | 11 398 (56.8) |
Regional | 102 914 (31.9) | 22 292 (37.7) | 7291 (36.3) |
Distant | 13 822 (4.3) | 2851 (4.8) | 1384 (6.9) |
Grade (n, %) | |||
Moderately differentiated; grade II | 138 937 (43.1) | 24 491 (41.4) | 9346 (46.6) |
Poorly differentiated; grade III | 105 361 (32.7) | 23 237 (39.2) | 7350 (36.6) |
Well differentiated; grade I | 73 815 (22.9) | 10 607 (17.9) | 3012 (15.0) |
Undifferentiated; anaplastic; grade IV | 4235 (1.3) | 869 (1.5) | 365 (1.8) |
Regional lymph nodes examined (n, %) | |||
0–9 | 233 642 (72.5) | 39 268 (66.3) | 13 679 (68.1) |
10–19 | 61 685 (19.1) | 13 312 (22.5) | 4470 (22.3) |
20–29 | 17 330 (5.4) | 4167 (7.0) | 1163 (5.8) |
Other | 6275 (1.9) | 1547 (2.6) | 549 (2.7) |
30–39 | 2837 (0.9) | 740 (1.2) | 176 (0.9) |
40+ | 579 (0.2) | 170 (0.3) | 36 (0.2) |
Oestrogen receptor status (n, %) | |||
Positive | 249 656 (77.4) | 43 494 (73.5) | 13 168 (65.6) |
Negative | 56 876 (17.6) | 12 575 (21.2) | 5941 (29.6) |
Borderline/unknown | 15 071 (4.7) | 2925 (4.9) | 915 (4.6) |
N/A | 745 (0.2) | 210 (0.4) | 49 (0.2) |
Progesterone receptor status (n, %) | |||
Positive | 210 985 (65.5) | 36 867 (62.3) | 10 463 (52.1) |
Negative | 90 699 (28.1) | 18 369 (31.0) | 8224 (41.0) |
Borderline/unknown | 19 919 (6.2) | 3758 (6.3) | 1337 (6.7) |
N/A | 745 (0.2) | 210 (0.4) | 49 (0.2) |
Chemotherapy (n, %) | |||
Y | 185 019 (57.4) | 30 197 (51.0) | 10 038 (50.0) |
N | 137 329 (42.6) | 29 007 (49.0) | 10 035 (50.0) |
Radiation (n, %) | |||
None/unknown | 150 350 (46.6) | 29 136 (49.2) | 9965 (49.6) |
Beam radiation | 147 114 (45.6) | 25 651 (43.3) | 8429 (42.0) |
Recommended, unknown if administered | 10 290 (3.2) | 2532 (4.3) | 922 (4.6) |
Refused | 5901 (1.8) | 796 (1.3) | 403 (2.0) |
Radioactive implants | 5897 (1.8) | 645 (1.1) | 191 (1.0) |
Radiation, NOS method or source not specified | 2415 (0.7) | 367 (0.6) | 150 (0.7) |
Other | 381 (0.1) | 77 (0.1) | 13 (0.1) |
Sequence of radiation and surgery performed (n, %) | |||
No radiation and/or cancer-directed surgery | 168 694 (52.3) | 32 906 (55.6) | 11 505 (57.3) |
Radiation after surgery | 149 615 (46.4) | 25 718 (43.4) | 8340 (41.5) |
Intraoperative radiation | 1839 (0.6) | 173 (0.3) | 68 (0.3) |
Radiation prior to surgery | 728 (0.2) | 168 (0.3) | 80 (0.4) |
Radiation before and after surgery | 673 (0.2) | 146 (0.2) | 40 (0.2) |
Intraoperative rad with other rad before/after surgery | 560 (0.2) | 53 (0.1) | 28 (0.1) |
Other | 239 (0.1) | 40 (0.1) | 12 (0.1) |
Reason no cancer-directed surgery (n, %) | |||
Surgery performed | 305 404 (94.7) | 55 371 (93.5) | 18 308 (91.2) |
Not recommended | 13 032 (4.0) | 2952 (5.0) | 1356 (6.8) |
Recommended, unknown if performed | 1899 (0.6) | 568 (1.0) | 217 (1.1) |
Recommended but not performed, patient refused | 1364 (0.4) | 211 (0.4) | 146 (0.7) |
Not recommended, contraindicated due to other | 333 (0.1) | 53 (0.1) | 22 (0.1) |
conditions, autopsy only | 285 (0.1) | 44 (0.1) | 22 (0.1) |
Other | 31 (0.0) | 5 (0.0) | 2 (0.0) |
N/A, not available.